← Scholar Rock Holding Corporation (SRRK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Scholar Rock Holding Corporation (SRRK)
Biological Products, (No Diagnostic Substances) · market cap $6.1B · as of 2026-08-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Scholar Rock (SRRK) is a ~$6.5B-cap biologics company whose value is concentrated in apitegromab, a Phase 3 myostatin-pathway antibody for spinal muscular atrophy (SMA). The company carries a near-term PDUFA (2026-09-30, importance 8/10) and an estimated Phase 3 readout (~2026-11-01, importance 9/10) per our calendar, against $430.5M cash and roughly 15.7 months of runway. It also holds early-stage optionality in obesity via a tirzepatide-adjacent Phase 2 program.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SRK-015 | Phase 2 | Spinal Muscular Atrophy |
| Apitegromab | Phase 3 | Spinal Muscular Atrophy |
Price & technical context
3-month
-15.9%
6-month
-6.5%
12-month
+24.0%
52-wk range
$27.92–$60.04
vs 50-day MA
-11.5%
vs 200-day MA
-4.6%
Realized vol
57.5%
Max drawdown
-47.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SRRK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.